Amgen to acquire Forbion-backed Dezima for up to $1.55 bln

Amgen Inc has agreed to buy Dezima Pharma from Forbion Capital Partners and other shareholders for up to $1.55 billion. Also included in the deal is an upfront payment of $300 million. Based in The Netherlands, Dezima develops drugs that treat dyslipidemic patients suffering from cardiovascular disease.

DealsNorth AmericaUSBriefs